Same protein levels, different cognitive trajectories
In laboratories in South Korea, researchers have found a quiet but consequential clue buried in the human genome — a variant on chromosome 6 that appears to erode the mind through pathways long overlooked by science. Published in Neurology, the finding challenges the decades-long assumption that Alzheimer's disease is primarily a story of protein accumulation, suggesting instead that the brain's vulnerability is written in multiple biological languages. For the nearly 50 million people living with dementia worldwide, this discovery opens a door that protein-focused research has never been able to unlock.
- Decades of Alzheimer's research built around amyloid-beta and tau proteins have yet to yield effective treatments, leaving millions without meaningful options.
- A genetic variant on chromosome 6 disrupts glutathione — a key antioxidant — causing cortical thinning and cognitive decline entirely independent of those protein markers.
- Among variant carriers with amyloid deposits, 49% developed Alzheimer's compared to 29% of non-carriers, a stark gap that the traditional protein model cannot explain.
- The variant alone accounts for roughly 5% of cognitive variation, a significant signal in a disease whose complexity has long defied single-cause explanations.
- Researchers are now pointing toward oxidative stress and antioxidant metabolism as viable therapeutic targets, potentially redirecting the field toward new classes of treatment.
South Korean researchers have identified a genetic variant that drives cognitive decline through a mechanism entirely separate from the protein accumulation long considered Alzheimer's primary cause. Published in Neurology, the finding suggests that understanding how the brain deteriorates may require looking well beyond the amyloid-beta plaques and tau tangles that have dominated the field for decades.
The variant, located on chromosome 6, disrupts the body's handling of glutathione — an antioxidant that shields brain cells from damage. Carriers show measurable thinning of the cerebral cortex and perform worse on cognitive tests. Crucially, this effect appears independent of protein deposits: two people with identical amyloid and tau levels can follow very different cognitive trajectories depending on whether they carry this variant.
The research team, led by Yong Jeong at South Korea's Advanced Institute of Science and Technology, studied 486 people who all had amyloid-beta deposits. The single variant they identified accounted for approximately 5% of the variation in cognitive function across the group. The numbers were striking: 49% of variant carriers had developed Alzheimer's disease, compared to just 29% of non-carriers — a disparity that persisted even with similar protein levels in both groups.
Jeong emphasized that traditional protein markers may be necessary for an Alzheimer's diagnosis but are not sufficient on their own to cause decline. The brain's deterioration, it seems, involves multiple biological pathways. Understanding how this variant affects antioxidant metabolism and cortical thickness could open new treatment avenues — targeting oxidative stress rather than protein clearance alone, and offering fresh hope in a field that has long struggled to translate decades of research into effective therapies.
South Korean researchers have identified a genetic variant that appears to drive cognitive decline through a mechanism entirely separate from the protein accumulation long thought to be Alzheimer's disease's primary culprit. The finding, published in Neurology, suggests that understanding how the brain deteriorates may require looking beyond the amyloid-beta plaques and tau tangles that have dominated Alzheimer's research for decades.
The variant sits on chromosome 6 and disrupts the body's handling of glutathione, an antioxidant that protects brain cells from damage. People who carry this variant show thinning of the cerebral cortex—the brain region responsible for memory and thinking—and perform worse on cognitive tests. What makes this discovery significant is that the genetic effect appears independent of the two protein deposits typically associated with Alzheimer's. Two people can have identical amounts of amyloid-beta and tau in their brains, yet the one carrying this genetic variant will likely experience greater cognitive decline.
The research team, led by Yong Jeong at South Korea's Advanced Institute of Science and Technology, studied 486 people who all had amyloid-beta deposits in their brains. Some maintained normal thinking and memory abilities. Others showed mild cognitive impairment. Still others had developed Alzheimer's disease itself. Using genetic analysis, the researchers identified variants linked to mental function independent of the protein markers. The single genetic variant they identified accounted for approximately 5 percent of the variation in cognitive function across the group.
The numbers tell a stark story. Among people carrying the variant, only 11 percent maintained normal cognitive abilities, compared to 25 percent of those without it. Mild impairment appeared in 40 percent of variant carriers versus 46 percent of non-carriers. But the most striking difference emerged at the disease end: 49 percent of those with the variant had developed Alzheimer's disease, compared to just 29 percent of those without it. This disparity persisted even though both groups had similar levels of amyloid-beta and tau in their brains.
Jeong emphasized that the traditional protein markers may be necessary for an Alzheimer's diagnosis but are not sufficient on their own to cause cognitive decline and dementia. The implication is that the brain's deterioration involves multiple biological pathways, not just protein accumulation. Understanding these additional mechanisms—particularly how genetic variants affect antioxidant metabolism and cortical thickness—could open entirely new avenues for treatment. Rather than focusing exclusively on clearing amyloid-beta or tau, researchers might develop drugs that address the oxidative stress and cellular damage that this genetic variant appears to trigger. For a disease that has resisted effective treatment despite decades of protein-focused research, identifying alternative biological mechanisms represents a potential turning point.
Notable Quotes
Protein deposits may be necessary for an Alzheimer's diagnosis, but they are not sufficient by themselves to cause cognitive decline and dementia— Yong Jeong, Advanced Institute of Science and Technology, South Korea
Understanding the genetic mechanisms underlying Alzheimer's development could lead to new treatments for this devastating disease— Yong Jeong
The Hearth Conversation Another angle on the story
Why does it matter that this genetic effect works independently of the protein deposits? Aren't those proteins still the main problem?
The proteins might be necessary but not sufficient. Think of it like a fire—you need oxygen, fuel, and heat. Scientists have been trying to remove the fuel, but this variant suggests there's another way the fire spreads, through oxidative damage. You could remove all the fuel and the fire might still burn.
So people with this variant have the same amount of protein buildup as people without it, but worse outcomes?
Exactly. Same protein levels, different cognitive trajectories. That's the puzzle. It means the variant is doing something else—damaging cells through oxidative stress, thinning the cortex—that compounds whatever the proteins are doing.
What's glutathione, and why does it matter that this variant disrupts it?
Glutathione is the brain's cleanup crew for oxidative damage. When cells burn energy, they create toxic byproducts. Glutathione neutralizes them. If the variant impairs that system, cells accumulate damage faster, even if the protein deposits are identical.
Could this lead to treatments that don't target the proteins at all?
Potentially. If you could boost glutathione metabolism or protect cells from oxidative stress, you might slow cognitive decline in people with this variant, regardless of their amyloid and tau levels. That's a completely different drug target.
How confident are researchers that this variant is actually causing the problem, not just associated with it?
The association is strong—49 percent of carriers developed Alzheimer's versus 29 percent of non-carriers. But causation is harder to prove. They've shown the variant correlates with cortex thinning and cognitive decline. The next step would be animal studies or cell models to show the mechanism directly.